Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Bladder-sparing treatment shows promise against cancer, maintains quality of life


For patients with invasive bladder cancer, treatment has typically meant an operation to remove the bladder and nearby organs. This requires up to a week in the hospital and leaves patients with a reconstructed bladder or urostomy bag.

Minimally invasive surgery combined with chemotherapy and radiation therapy has potential in some patients to cure the cancer but preserve the bladder. A new pilot study by University of Michigan Health System researchers found combining radiation therapy and a chemotherapy drug that is used successfully with other forms of cancer may effectively treat bladder cancer without toxic reactions, while allowing many patients to preserve their bladder.

Results of the study appeared in two papers published this month. The first paper, published in the Journal of Clinical Oncology, tested appropriate doses of the chemotherapy drug gemcitabine. The second paper, published in Urology, looked at quality of life.

Instead of cystectomy, surgery that removes the entire bladder, 24 patients with muscle invasive cancer confined to the bladder underwent transurethral surgery, a procedure that involves no incision, to remove the tumor cells. Patients then received low doses of gemcitabine along with radiation therapy for six weeks. The radiation was given once daily, five days a week; chemotherapy was given twice each week throughout the six weeks.

By monitoring toxic reactions such as low blood counts, the researchers were able to determine the dose at which patients could tolerate combined gemcitabine and radiation therapy. All but two patients showed no signs of cancer at their first follow-up screening. About four years later, 65 percent of the patients were still cancer-free – similar to results with more aggressive surgery – and they still had intact bladders.

"The exciting part of this study is we were able to use gemcitabine at a dose that increases the effectiveness of radiation without causing significant toxicities – and 16 of 24 patients kept their bladder," says study author David C. Smith, M.D., associate professor of internal medicine and urology at U-M Medical School and medical director of the Multidisciplinary Urologic Oncology Clinic at the U-M Comprehensive Cancer Center.

Smith emphasizes that this approach, which is still experimental, will likely work best on certain types of patients, namely those whose disease has not spread outside the bladder and who do not have a condition called carcinoma in situ. It may also be an option for patients who cannot have surgery because of a large tumor or other medical conditions.

Previous studies have looked at radiation alone to treat bladder cancer, but results were not promising. Other chemotherapy drugs in combination with radiation therapy have been used, but the chemotherapy regimen is too difficult for many patients to finish. When radiation and chemotherapy are administered ineffectively, patients end up needing surgery to remove their bladders anyway.

The U-M team chose gemcitabine because it has been shown to make radiation more effective at killing cancer cells and generally does not cause severe side effects. Few study participants had toxic reactions, including bladder inflammation, low blood counts and liver damage, and most were able to receive full doses of chemotherapy throughout their radiation therapy. Gemcitabine has been used along with radiation therapy to treat pancreatic cancer and head and neck cancers.

Study participants completed questionnaires about quality of life before treatment began, during their six weeks of treatment and after they completed treatment. Questionnaires asked about physical, emotional, social and functional well-being and included questions specific to bladder cancer patients about urinary and bowel control. The researchers found no statistically significant differences in responses before, during or after treatment.

"Patients were able to finish the entire treatment regimen and the majority reported few changes in urinary urgency, bowel control and erectile function. Our results suggest gemcitabine with radiation therapy may be an effective way to treat bladder cancer in selected patients," says study author Howard Sandler, M.D., professor of radiation oncology at U-M Medical School.

Bladder preservation using gemcitabine and radiation is not currently offered to patients outside of clinical trials, and radical cystectomy remains the standard approach for most bladder cancer patients. Researchers are planning a larger, multicenter phase II study to further determine whether gemcitabine with radiation is a good option for treating bladder cancer.

Nicole Fawcett | EurekAlert!
Further information:

More articles from Studies and Analyses:

nachricht Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung

nachricht High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>